In This Issue
Cancer Discov June 1 2016 6 (6) 561-563; DOI:10.1158/2159-8290.CD-ITI6-6
Recurrent oncogenic BRAFV600E mutations in patients with advanced colorectal NETs may be targeted with combination BRAF/MEK inhibitors to achieve rapid and sustained clinical improvement.
Oncogenic EGFR fusions were identified by next-generation sequencing in several patients with metastatic lung cancer, and these patients responded to EGFR inhibitor therapy.
Oncogene-induced senescence promotes enhancer remodeling and BRD4 binding at senescence-associated secretory phenotype genes, which drives paracrine signaling and immune surveillance.
Neutrophils facilitate the intermediate stages of the invasion–metastasis cascade by suppressing NK-cell activity and promoting extravasation of carcinoma cells.
PDX shRNA screens of patient-derived melanomas identified significant interpatient heterogeneity in essential, nonmutated genes.
Early cytokine measurements can accurately predict which patients will develop severe cytokine release syndrome following chimeric antigen receptor T-cell therapy.